Key Highlights
- Shares closed at $6.86 at last closing, up 6.52%.
- Second-quarter 2026 total Revenue was about $29 million, down modestly year over year and generated by its Chinese product business, with the net loss widening to around $14 million.
- The company's lead candidate, F351 (Hydronidone), had its new-drug application accepted by China's regulator, with priority review, for liver fibrosis.
- Gyre Therapeutics affirmed its full-year 2026 revenue guidance, with cash and investments of roughly $103 million.
Gyre Therapeutics (NASDAQ:GYRE) is a biopharmaceutical company created through a Reverse merger with the former Catalyst Biosciences, whose operations are centered on its China-based subsidiary, giving it substantial commercial product revenue unusual for a US-listed biopharma. Shares closed at $6.86 at last closing, up 6.52%.
Its lead program is F351, or Hydronidone, for liver fibrosis, and its results depend on its Chinese product revenue, its research-and-development spending, its cash, and the regulatory progress of F351 in China, making this a China-regulatory story rather than a US-FDA story.
Latest Developments
In its second-quarter 2026 results, Gyre Therapeutics reported total revenue of about $29 million, down modestly year over year and generated by its Chinese product business, with its net loss widening, to around $14 million, on higher research-and-development and transaction costs, and cash and investments of roughly $103 million. Its lead catalyst is F351, whose new-drug application was accepted by China's regulator, with priority review, for liver fibrosis. The company affirmed its full-year 2026 revenue guidance. Investors should verify the latest product revenue, the regulatory status of F351, and the cash and Investment position directly from SEC filings.
Financial and Business Position
Gyre's investment case rests on its Chinese product-revenue base, the regulatory progress of F351 for liver fibrosis, and its cash and investments, balanced against flat-to-lower revenue and widening losses as it invests. Investors should watch product revenue, the net loss and cash burn, and the regulatory status and potential approval of F351.
Stock-Market Context
GYRE shares closed at $6.86 at last closing, up 6.52%. The stock is a biopharma whose shares are sensitive to Chinese regulatory news and product-revenue trends, and its concentration in China adds regulatory and geopolitical considerations.
What Investors Should Watch
Watch product revenue, the net loss and cash burn, the cash and investment position, the regulatory status and potential approval of F351 for liver fibrosis, and guidance. A favorable Chinese regulatory decision on F351, combined with a stable product-revenue base, would be the catalyst most likely to change the story.


_11_18_2026_14_40_45_405856.jpg)



Please wait processing your request...